Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients

• Conditions: hypertensionmetabolic syndrome; MedDRA version: 9.1Level: LLTClassification code 10020772Term: Hypertension; MedDRA version: 9.1Level: LLTClassification code 10052066Term: Metabolic syndrome

• Registration Number: EUCTR2006-003567-31-DE
• Lead Sponsor: Med. Klinik II, Grosshadern, Klinikum der Universität München

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-03-29
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

age 19-60 yearsAlter 19-60 Jahre
abdominal obesity (BMI > 25 kg/m² and waist circumference>=95 cm (male), >=80 cm (female))
systolic blood pressure >=130mmHg and/or diastolic blood pressure >=85mmHg
Triglycerides 150-400 mg/dl

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Diabetes mellitus (fasting glucose >=126 mg/dl or antidiabetic medication)
secondary causes for insulin resistence (e.g. corticosteroids)
LDL-cholesterol > 190 mg/dl
established atherosclerosis
systolic blood pressure >=160mmHg and/or diastolic blood pressure >=100mmHg
regular alcohol consumption > 30g/d
contra-indications agains ARB
anti-hypertensive medication
lipid-lowering therapy
pregnant or breast-feeding women
Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and up to four weeks after the study in such a manner that the risk of pregnancy is minimized.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified